$28.67+0.61 (+2.17%)
Avalyn Pharma Inc.
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Avalyn Pharma Inc. operates as a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases. The company provides inhaled formulations of...
Avalyn Pharma (NASDAQ:AVLN) executives outlined the company’s inhaled pulmonary fibrosis strategy at the Jefferies Global Healthcare Conference, emphasizing its recent IPO, ongoing mid-stage studies and plans to position its candidates as potential backbone therapies for idiopathic pulmonary fibrosi
Why Avalyn Pharma is on investors’ radar Avalyn Pharma (AVLN) has drawn attention after recent share price moves, with the stock last closing at $28.78 and showing mixed short term returns over the past week and month. See our latest analysis for Avalyn Pharma. While the 1 day share price return of 1.37% contrasts with weaker 7 day, 30 day and year to date share price returns, the pattern suggests recent momentum is still subdued after earlier gains. If you are watching Avalyn and want to see...
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...